USFDA10 Feb 2026, 10:11 pm
Aurobindo Pharma's Unit-VII Receives US FDA Inspection with 9 Procedural Observations
AI Summary
Aurobindo Pharma Ltd. has received a completion notification of a US FDA inspection at its Unit VII in Jedcherla, Telangana. The inspection, conducted from January 28 to February 10, 2026, resulted in a 'Form 483' with 9 procedural observations. The company is committed to maintaining high manufacturing standards and will respond to the US FDA within the stipulated timelines.
Key Highlights
- US FDA inspected Aurobindo Pharma’s Unit-VII from January 28 to February 10, 2026
- A total of 9 observations were issued, all of procedural nature
- The company is committed to maintaining high quality manufacturing standards
- Aurobindo Pharma will respond to the US FDA within the stipulated timelines